Abstracts tagged "interstitial lung disease"

Abstract Number: 0154 • ACR Convergence 2024
Chronic Sinusitis Predicting Interstitial Lung Disease in Sjögren’s Syndrome: A Comprehensive USA Population Study (2004-2024)
Brian Schonewald¹, Ross summer², Giorgos Loizidis² and Christopher Xie³, ¹Thomas Jefferson University Hospital, Ardmore, PA, ²Thomas Jefferson University, Philadelphia, PA, ³Thomas Jefferson University, Philadelphia
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disorder primarily affecting the exocrine glands, but it also impacts various parts of the respiratory system, including…
Abstract Number: 0470 • ACR Convergence 2024
New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers
Veronica Pulito-Cueto¹, Belén Atienza-Mateo², gonzalo Ocejo-Viñals³, Victor M. Mora-Cuesta⁴, David Iturbe-Fernández⁴, Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil⁵, Mónica Renuncio-García⁶, Elena González López³, José M. Cifrián⁷, Ricardo Blanco-Alonso⁸ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁴Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁵Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁶Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of death in rheumatoid arthritis (RA) patients [1]. Early diagnosis of RA-ILD+ is critical…
Abstract Number: 0802 • ACR Convergence 2024
Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study
Gregory McDermott¹, Ritu Gill², Suzanne Byrne³, Staci Gagne³, Xiaosong Wang⁴, Misti Paudel⁵, Emily Kowalski³, Grace Qian⁴, Katarina Bade³, Kevin Mueller³, Alene Saavedra³, Kathleen Vanni³, Caleb Bolden⁶, Tina Mahajan⁷, Erica Mulcaire-Jones⁸, Neda Kortam⁸, Pierre-Antoine Juge⁹, Tracy J Doyle¹⁰, Zachary Wallace¹¹, Marcy Bolster⁶, Kevin Deane¹², Dinesh Khanna⁸, Bryant England⁷ and Jeffrey Sparks¹³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁶Massachusetts General Hospital, Boston, MA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸University of Michigan, Ann Arbor, MI, ⁹Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ¹⁰Brigham and Women's Hospital, West Roxbury, MA, ¹¹Massachusetts General Hospital, Newton, MA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA is associated with several forms of lung disease including interstitial lung disease (ILD), bronchiectasis, and emphysema. Risk factors for the development and progression…
Abstract Number: 1007 • ACR Convergence 2024
Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis
Connor Buechler, Lindsey Wanberg, Nawang Singhe, Cody Rasner, Joseph McGrath, Ziou Jiang, Karen Baker-James and David Pearson, University of Minnesota, Minneapolis, MN
Background/Purpose: Dermatomyositis (DM) is associated with significant morbidity and mortality due to disease-related progressive interstitial lung disease (ILD) and malignancy. However, little is known about…
Abstract Number: 1571 • ACR Convergence 2024
Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Vishal Kakkar¹, Sunhwa Kim², Yingtao Bi³, Christopher Wasson¹, Stefano Di Donato⁴, Rebecca Ross⁵, Marco Di Battista⁶, Enrico De Lorenzis⁷, Thierry Sornasse² and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²AbbVie, South San Francisco, CA, ³Abbvie, Worcester, MA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁵Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Pisa, United Kingdom, ⁷Catholic University of the Sacred Heart, Roma, Rome, Italy
Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…
Abstract Number: 1894 • ACR Convergence 2024
Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System
Gregory McDermott¹, Mark Hammer², Xiaosong Wang³, Misti Paudel⁴, Sung Hae Chang⁵, Pierre-Antoine Juge⁶, Qianru Zhang⁷, Jessica Lorusso⁸, Amie Samulyov⁸, Kathleen Vanni², Alene Saavedra², Emily Kowalski², Grace Qian³, Katarina Bade², Kevin Mueller², Jeffrey Sparks⁹ and Suzanne Byrne², ¹Brigham and Women's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ⁶Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁷Harard Medical School, Cambridge, ⁸Mass General Brigham, Boston, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Cigarette smoking is a risk factor for both lung cancer and RA. Furthermore, RA is associated with pulmonary abnormalities including interstitial lung disease, bronchiectasis,…
Abstract Number: 2284 • ACR Convergence 2024
Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Jesús Loarce³, Nuria Vegas Revenga⁴, María Martín López⁵, Santos Castañeda⁶, Rafael Benito Melero-Gonzalez⁷, Natalia Mena Vázquez⁸, Carmen Carrasco-Cubero⁹, Carolina Díez Morrondo¹⁰, David Castro-Corredor¹¹, Tomás Vázquez Rodríguez¹², Andrea García-Valle¹³, Gema Bonilla¹⁴, Marina Rodriguez¹⁵, Ignacio Brana Abascal¹⁶, Sara María Rojas Herrera¹⁷, Juan Camilo Sarmiento-Monroy¹⁸, Pablo Andújar-Brazal¹⁹, Diego Ferrer²⁰ and Ricardo Blanco-Alonso²¹, and Rest of the Members of the Spanish Collaborative Group of Antifibrotics in Interstitial Lung Disease Associated with Rheumatoid Arthritis, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ⁵General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷CHU Ourense, O Carballino, Spain, ⁸IBIMA, Málaga, Andalucia, Spain, ⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹⁰Complejo Asistencial Universitario de Leon, Leon, ¹¹General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹²Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ¹³Hospital General Río Carrión, Palencia, Spain, ¹⁴H. Universitario La Paz, Madrid, Spain, ¹⁵Hospital Clínico Universitario de Santiago, La Coruna, Spain, ¹⁶Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ¹⁷Hospital de Mérida, Badajoz, Spain, ¹⁸Hospital Clínic Barcelona, Barcelona, Spain, ¹⁹Hospital Universitario Doctor Peset, Valencia, Spain, ²⁰Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA), with a prevalence that ranges from 7 to 30% patients with RA,…
Abstract Number: 2665 • ACR Convergence 2024
Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima¹, Atsubumi Ogawa², Motohiro Nonaka², Norimichi Nomura², Yasuhiro Nohda², Mirei Shirakashi³, Ryosuke Hiwa², Hideaki Tsuji¹, Shuji Akizuki⁴, Hajime Yoshifuji¹, Tsuneyo Mimori⁵ and Akio Morinobu⁶, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Kyoto University, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁵Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD), leading to poor prognosis. Initial combinational therapy…
Abstract Number: 0214 • ACR Convergence 2024
Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Justin Dunn¹, Scott Matson², Michael George³, Yangyuna Yang¹, Punyasha Roul⁴, Jorge Rojas⁵, grant Cannon⁶, Sauer brian⁷, Jeffrey Curtis⁸, Joshua Baker³, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Kansas, Kansas City, MO, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵Seattle VA, Mexico, Mexico, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁸University of Alabama at Birmingham, Hoover, AL
Background/Purpose: The American College of Rheumatology (ACR) and American College of Chest Physicians (CHEST) recently released clinical practice guidelines for the treatment of RA-interstitial lung…
Abstract Number: 0477 • ACR Convergence 2024
The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Hari Prasanna¹, Charles Inderjeeth², Johannes Nossent³ and KHALID ALMUTAIRI⁴, ¹University of Western Australia, Perth, Western Australia, Australia, ²SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia, ³University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ⁴The University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of rheumatoid arthritis (RA) that severely impacts the health outcomes of RA patients. Despite this, the…
Abstract Number: 0803 • ACR Convergence 2024
Serum Adipokines and Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort
Anna Haggart¹, Joshua Baker², Tate Johnson³, Yangyuna Yang³, Punyasha Roul⁴, Katherine Wysham⁵, grant Cannon⁶, Gary Kunkel⁷, Dana Ascherman⁸, Paul Monach⁹, Gail Kerr¹⁰, Andreas Reimold¹¹, Michael Duryee³, Geoffrey Thiele³, Ted Mikuls³ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Dallas VA Medical Center, Dallas, TX
Background/Purpose: Adipokines are metabolic cytokines shown to be dysregulated in RA and prognostic of RA-related complications such as cardiovascular disease. Similarly, aberrations in adipokines have…
Abstract Number: 1105 • ACR Convergence 2024
PDGFA and TGFB1, Key Genes to Discriminate Autoimmune Diseases-Related Interstitial Lung Disease from Idiopathic Pulmonary Fibrosis?
Veronica Pulito-Cueto¹, Belén Atienza-Mateo², David Iturbe-Fernández³, Victor M. Mora-Cuesta³, Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil⁴, José M. Cifrián⁵, Ricardo Blanco-Alonso⁶ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁴Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the main causes of mortality in patients with autoimmune diseases (ADs) [1]. The early diagnosis of AD-ILD+…
Abstract Number: 1575 • ACR Convergence 2024
Anti-U1RNP Antibodies Are Associated with a Distinct Clinical Phenotype and a Worse Survival in Patients with Systemic Sclerosis
Kevin Chevalier¹, Guillaume Chassagnon², Sarah LOUIS-LEONARD³, Pascal cohen⁴, bertrand Dunogue⁵, Alexis Régent⁶, Benjamin Thoreau⁵, Luc Mouthon⁵ and Benjamin Chaigne⁷, ¹Paris Cardiovascular Research Center, INSERM U970, Paris, France, ²Department of Radiology, Hôpital Cochin, AP-HP. Centre Université Paris Cité, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France, Paris, France, ³Sorbonne Université, INSERM, Department of Neurormyologie and Neuropathology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁷Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic disease within the connective tissue disease (CTD) spectrum. It is characterized by microcirculatory abnormalities, skin and internal…
Abstract Number: 1905 • ACR Convergence 2024
Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
Bryant England¹, Austin Wheeler¹, Brent Luedders¹, Michael Duryee¹, Halie Frideres², Katherine Wysham³, grant Cannon⁴, Gary Kunkel⁵, Dana Ascherman⁶, Paul Monach⁷, Gail Kerr⁸, Andreas Reimold⁹, Joshua Baker¹⁰, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷VA Boston Healthcare System, Boston, MA, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
Background/Purpose: Several peripheral biomarkers for RA-associated interstitial lung disease (RA-ILD) have been evaluated to enhance early RA-ILD identification. The MUC5B rs35705950 promoter variant, matrix metalloproteinase-7…
Abstract Number: 2299 • ACR Convergence 2024
Clinical and Serological Characteristics of Sjögren’s Disease-related Lymphocytic Interstitial Pneumonia: A Large Multicenter Study
Gaetano La Rocca¹, Francesco Ferro², Marco Sebastiani³, Andreina Manfredi⁴, Caterina Vacchi⁵, Elena Bartoloni Bocci⁶, Martina Nicchi⁷, Fabiola Atzeni⁸, Francesca Cracò⁹, Serena Guiducci¹⁰, Laura Cometi¹¹, Luca Quartuccio¹², Elena Treppo¹², Valeria manfrè¹³, Marta Mosca¹ and Chiara Baldini¹, and Italian Study group on Lung iNvolvement in rheumatic Diseases (ISLaND), ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³Rheumatology Unit, Azienda USL of Piacenza and University of Parma, Parma, Italy, ⁴University of Modena and Reggio Emilia, Modena, ⁵University of Modena and Reggio Emilia, Modena, Italy, ⁶Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁷Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, ⁸University of Messina, Italy, Messina, Italy, ⁹University of Messina, Messina, Italy, ¹⁰University of Florence, Pistoia, Italy, ¹¹University of Florence, Florence, Italy, ¹²Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ¹³University of Udine, Udine
Background/Purpose: Interstitial Lung Disease (ILD) in patients with Primary Sjögren’s Disease (SjD) is very heterogeneous in terms of pathophysiologic mechanisms, clinical course, radiologic and histologic…

1
2
3
…
39
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].